Ignite Creation Date:
2025-12-24 @ 9:49 PM
Ignite Modification Date:
2026-01-05 @ 5:50 PM
Study NCT ID:
NCT00598832
Status:
COMPLETED
Last Update Posted:
2021-02-18
First Post:
2008-01-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000152', 'term': 'Acne Vulgaris'}], 'ancestors': [{'id': 'D017486', 'term': 'Acneiform Eruptions'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D012625', 'term': 'Sebaceous Gland Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'michael.graeber@galderma.com', 'phone': '609-860-8201', 'title': 'Michael Graeber MD/ Head of Global Clinical Project Management', 'organization': 'Galderma'}, 'certainAgreement': {'otherDetails': 'disclosure restriction varies per institutional request/agreement', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'Adapalene Lotion 0.1%', 'description': 'once a day for 12 weeks', 'otherNumAtRisk': 533, 'otherNumAffected': 50, 'seriousNumAtRisk': 533, 'seriousNumAffected': 2}, {'id': 'EG001', 'title': 'Adapalene Lotion Vehicle 0%', 'description': 'once a day for 12 weeks', 'otherNumAtRisk': 542, 'otherNumAffected': 21, 'seriousNumAtRisk': 542, 'seriousNumAffected': 2}], 'otherEvents': [{'term': 'Dry skin', 'stats': [{'groupId': 'EG000', 'numAtRisk': 533, 'numEvents': 50, 'numAffected': 50}, {'groupId': 'EG001', 'numAtRisk': 542, 'numEvents': 21, 'numAffected': 21}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'Multiple drug overdose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 533, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 542, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Cerebral hemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 533, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 542, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Suicide attempt', 'stats': [{'groupId': 'EG000', 'numAtRisk': 533, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 542, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Ovarian cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 533, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 542, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 533, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 542, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': "Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12", 'denoms': [{'units': 'Participants', 'counts': [{'value': '533', 'groupId': 'OG000'}, {'value': '542', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Adapalene Lotion 0.1%', 'description': 'once a day for 12 weeks'}, {'id': 'OG001', 'title': 'Adapalene Lotion Vehicle 0%', 'description': 'once a day for 12 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '26.3', 'groupId': 'OG000'}, {'value': '17.3', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Baseline to Week 12', 'description': 'Success defined as percentage of subjects who achieved at least a two-grade reduction in IGA scale (e.g from moderate to clear or almost clear)at week 12 from baseline, Last Observation Carried Forward, Intent to treat population. The IGA (Investigator Global Assessment) is defined as a 5 point scale (0 to 4). "0" = clear , "1"= almost clear, "2"= mild, "3"= moderate, "4"=severe.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Mean Percent Change in Total Lesion Count From Baseline to Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '533', 'groupId': 'OG000'}, {'value': '542', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Adapalene Lotion 0.1%', 'description': 'once a day for 12 weeks'}, {'id': 'OG001', 'title': 'Adapalene Lotion Vehicle 0%', 'description': 'once a day for 12 weeks'}], 'classes': [{'title': 'Total lesion count', 'categories': [{'measurements': [{'value': '-51.5', 'spread': '29.6', 'groupId': 'OG000'}, {'value': '-37.1', 'spread': '34.2', 'groupId': 'OG001'}]}]}, {'title': 'Inflammatory', 'categories': [{'measurements': [{'value': '-54.9', 'spread': '31.9', 'groupId': 'OG000'}, {'value': '-40.3', 'spread': '40.7', 'groupId': 'OG001'}]}]}, {'title': 'Non-Inflammatory', 'categories': [{'measurements': [{'value': '-49.6', 'spread': '34.0', 'groupId': 'OG000'}, {'value': '-35.7', 'spread': '38.0', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'From Baseline to Week 12', 'description': 'Percent change in lesion count from baseline to week 12', 'unitOfMeasure': '% Change in Lesion Count', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Co-Primary Endpoint: Absolute Change in Total Lesion Count From Baseline to Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '533', 'groupId': 'OG000'}, {'value': '542', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Adapalene Lotion 0.1%', 'description': 'once a day for 12 weeks'}, {'id': 'OG001', 'title': 'Adapalene Lotion Vehicle 0%', 'description': 'once a day for 12 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '36.7', 'spread': '1.0', 'groupId': 'OG000'}, {'value': '25.5', 'spread': '1.0', 'groupId': 'OG001'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to Week 12', 'unitOfMeasure': 'Absolute Change in Total Lesion Count', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Co-Primary Endpoint: Absolute Change in Inflammatory Lesion Count From Baseline to Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '533', 'groupId': 'OG000'}, {'value': '542', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Adapalene Lotion 0.1%', 'description': 'once a day for 12 weeks'}, {'id': 'OG001', 'title': 'Adapalene Lotion Vehicle 0%', 'description': 'once a day for 12 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '14.3', 'spread': '0.4', 'groupId': 'OG000'}, {'value': '10.2', 'spread': '0.4', 'groupId': 'OG001'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to Week 12', 'unitOfMeasure': 'Absolute Change in Infl Lesion count', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Co-Primary Endpoint: Absolute Change in NonInflammatory Lesion Counts From Baseline to Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '533', 'groupId': 'OG000'}, {'value': '542', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Adapalene Lotion 0.1%', 'description': 'once a day for 12 weeks'}, {'id': 'OG001', 'title': 'Adapalene Lotion Vehicle 0%', 'description': 'once a day for 12 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '22.4', 'spread': '0.8', 'groupId': 'OG000'}, {'value': '15.3', 'spread': '0.7', 'groupId': 'OG001'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline to Week 12', 'unitOfMeasure': 'Absolute Change in Non-Infl Lesion count', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Adapalene Lotion 0.1%', 'description': 'once a day for 12 weeks'}, {'id': 'FG001', 'title': 'Adapalene Lotion Vehicle 0%', 'description': 'once a day for 12 weeks'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '533'}, {'groupId': 'FG001', 'numSubjects': '542'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '471'}, {'groupId': 'FG001', 'numSubjects': '460'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '62'}, {'groupId': 'FG001', 'numSubjects': '82'}]}], 'dropWithdraws': [{'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '7'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '25'}, {'groupId': 'FG001', 'numSubjects': '36'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '24'}, {'groupId': 'FG001', 'numSubjects': '29'}]}, {'type': 'Pregnancy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '4'}]}, {'type': 'Non compliance', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'Multi center study recruitment period: First subject enrolled Nov 7, 2007; last subject completed Nov 6, 2008', 'preAssignmentDetails': 'Washout requirements: 2 weeks for systemic anti-inflammatory drugs, 4 weeks for oral antibiotics, 2 months for inhaled/nasal steroids and 6 months for hormonal contraceptives/therapies.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '533', 'groupId': 'BG000'}, {'value': '542', 'groupId': 'BG001'}, {'value': '1075', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Adapalene Lotion 0.1%', 'description': 'once a day for 12 weeks'}, {'id': 'BG001', 'title': 'Adapalene Lotion Vehicle 0%', 'description': 'once a day for 12 weeks'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '327', 'groupId': 'BG000'}, {'value': '343', 'groupId': 'BG001'}, {'value': '670', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '206', 'groupId': 'BG000'}, {'value': '199', 'groupId': 'BG001'}, {'value': '405', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '19.5', 'spread': '7.1', 'groupId': 'BG000'}, {'value': '18.9', 'spread': '6.5', 'groupId': 'BG001'}, {'value': '19.2', 'spread': '6.8', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '283', 'groupId': 'BG000'}, {'value': '290', 'groupId': 'BG001'}, {'value': '573', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '250', 'groupId': 'BG000'}, {'value': '252', 'groupId': 'BG001'}, {'value': '502', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '463', 'groupId': 'BG000'}, {'value': '468', 'groupId': 'BG001'}, {'value': '931', 'groupId': 'BG002'}]}]}, {'title': 'Canada', 'categories': [{'measurements': [{'value': '70', 'groupId': 'BG000'}, {'value': '74', 'groupId': 'BG001'}, {'value': '144', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1075}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2007-11'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2011-03', 'completionDateStruct': {'date': '2008-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-02-16', 'studyFirstSubmitDate': '2008-01-11', 'resultsFirstSubmitDate': '2010-04-16', 'studyFirstSubmitQcDate': '2008-01-11', 'lastUpdatePostDateStruct': {'date': '2021-02-18', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2011-03-21', 'studyFirstPostDateStruct': {'date': '2008-01-23', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2011-04-19', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2008-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': "Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12", 'timeFrame': 'From Baseline to Week 12', 'description': 'Success defined as percentage of subjects who achieved at least a two-grade reduction in IGA scale (e.g from moderate to clear or almost clear)at week 12 from baseline, Last Observation Carried Forward, Intent to treat population. The IGA (Investigator Global Assessment) is defined as a 5 point scale (0 to 4). "0" = clear , "1"= almost clear, "2"= mild, "3"= moderate, "4"=severe.'}, {'measure': 'Co-Primary Endpoint: Absolute Change in Total Lesion Count From Baseline to Week 12', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Co-Primary Endpoint: Absolute Change in Inflammatory Lesion Count From Baseline to Week 12', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Co-Primary Endpoint: Absolute Change in NonInflammatory Lesion Counts From Baseline to Week 12', 'timeFrame': 'Baseline to Week 12'}], 'secondaryOutcomes': [{'measure': 'Mean Percent Change in Total Lesion Count From Baseline to Week 12', 'timeFrame': 'From Baseline to Week 12', 'description': 'Percent change in lesion count from baseline to week 12'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Acne Vulgaris', 'Adapalene'], 'conditions': ['Acne Vulgaris']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine whether Adapalene, 0.1% is safe and effective in the treatment of Acne Vulgaris.', 'detailedDescription': "This study will compare the efficacy and safety of Adapalene, 0.1% and vehicle in the treatment of subjects with Acne Vulgaris. This is a multi-center, randomized, double-blind, parallel, vehicle controlled study involving subjects with acne vulgaris meeting pre-specified inclusion/exclusion criteria. Male and female subjects, 12 years of age or older, with 20-50 papules and pustules and 30 to 100 non-inflammatory lesions and have an Investigator's Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe) are eligible for enrollment. One nodule may be present at inclusion. Acne lesions are evaluated on the face only. Subjects presenting with facial and truncal acne vulgaris can participate in this study. Subjects will be randomized in a 1:1 ratio to Adapalene, 0.1% or Vehicle."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '12 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Subjects with Moderate or Severe Acne Vulgaris,\n* 20-50 papules and pustules in total on the face excluding the nose\n* 30-100 non-inflammatory lesions on the face excluding the nose.\n* Negative urine pregnancy test for all females.\n\nExclusion Criteria:\n\n* Subjects with more than one acne nodule.\n* Subjects with any acne cyst on the face.\n* Subjects with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or severe acne requiring systemic treatment.\n* Subjects with underlying diseases or other dermatologic conditions that require the use of interfering topical or systemic therapy, such as, but not limited to, atopic dermatitis, perioral dermatitis or rosacea.\n* Subjects who are pregnant, nursing, or planning a pregnancy.'}, 'identificationModule': {'nctId': 'NCT00598832', 'briefTitle': 'Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%', 'organization': {'class': 'INDUSTRY', 'fullName': 'Galderma R&D'}, 'officialTitle': 'A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Demonstrate the Efficacy and Safety of Adapalene Lotion, 0.1% Compared With Vehicle Lotion in Subjects With Acne Vulgaris', 'orgStudyIdInfo': {'id': 'RD.06.SPR.18113'}, 'secondaryIdInfos': [{'id': 'IND 076057'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Adapalene lotion 0.1%', 'interventionNames': ['Drug: Adapalene lotion 0.1%']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Adapalene Lotion vehicle', 'interventionNames': ['Drug: Adapalene Lotion Vehicle']}], 'interventions': [{'name': 'Adapalene lotion 0.1%', 'type': 'DRUG', 'description': 'Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks', 'armGroupLabels': ['Adapalene lotion 0.1%']}, {'name': 'Adapalene Lotion Vehicle', 'type': 'DRUG', 'description': 'Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks', 'armGroupLabels': ['Adapalene Lotion vehicle']}]}, 'contactsLocationsModule': {'locations': [{'zip': '71913', 'city': 'Hot Springs', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Burke Pharmaceutical Research', 'geoPoint': {'lat': 34.5037, 'lon': -93.05518}}, {'zip': '72205', 'city': 'Little Rock', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Scott Dinehart', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'zip': '90292', 'city': 'Marina del Rey', 'state': 'California', 'country': 'United States', 'facility': 'Dermatology and Laser Center', 'geoPoint': {'lat': 33.98162, 'lon': -118.45371}}, {'zip': '92123', 'city': 'San Diego', 'state': 'California', 'country': 'United States', 'facility': 'Therapeutics Clinical Research', 'geoPoint': {'lat': 32.71571, 'lon': -117.16472}}, {'zip': '94589', 'city': 'Vallejo', 'state': 'California', 'country': 'United States', 'facility': 'Solano Clinical Research', 'geoPoint': {'lat': 38.10409, 'lon': -122.25664}}, {'zip': '80210', 'city': 'Denver', 'state': 'Colorado', 'country': 'United States', 'facility': 'Colorado Medical Research Center', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'zip': '80501', 'city': 'Longmont', 'state': 'Colorado', 'country': 'United States', 'facility': 'Longmont Clinic', 'geoPoint': {'lat': 40.16721, 'lon': -105.10193}}, {'zip': '34711', 'city': 'Clermont', 'state': 'Florida', 'country': 'United States', 'facility': 'Advanced Dermatology', 'geoPoint': {'lat': 28.54944, 'lon': -81.77285}}, {'zip': '33144', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'International Dermatology Research, Inc.', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '30904', 'city': 'Augusta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Anne M. Loebl', 'geoPoint': {'lat': 33.47097, 'lon': -81.97484}}, {'zip': '60089', 'city': 'Buffalo Grove', 'state': 'Illinois', 'country': 'United States', 'facility': 'Scott Glazer', 'geoPoint': {'lat': 42.15141, 'lon': -87.95979}}, {'zip': '46617', 'city': 'South Bend', 'state': 'Indiana', 'country': 'United States', 'facility': 'Sound Bend Clinic', 'geoPoint': {'lat': 41.68338, 'lon': -86.25001}}, {'zip': '48060', 'city': 'Port Huron', 'state': 'Michigan', 'country': 'United States', 'facility': 'Hamzavi Dermatology', 'geoPoint': {'lat': 42.97086, 'lon': -82.42491}}, {'zip': '63117', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Central Dermatology, PC', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '03756', 'city': 'Lebanon', 'state': 'New Hampshire', 'country': 'United States', 'facility': 'Darmouth-Hitchcock Medical Center Section of Dermatology', 'geoPoint': {'lat': 43.64229, 'lon': -72.25176}}, {'zip': '87106', 'city': 'Albuquerque', 'state': 'New Mexico', 'country': 'United States', 'facility': 'Academic Dermatology', 'geoPoint': {'lat': 35.08449, 'lon': -106.65114}}, {'zip': '14609', 'city': 'Rochester', 'state': 'New York', 'country': 'United States', 'facility': 'Elizabeth Arthur', 'geoPoint': {'lat': 43.15478, 'lon': -77.61556}}, {'zip': '11790', 'city': 'Stony Brook', 'state': 'New York', 'country': 'United States', 'facility': 'Derm Research Center of New York', 'geoPoint': {'lat': 40.92565, 'lon': -73.14094}}, {'zip': '28601', 'city': 'Hickory', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Unifour Medical Research Associates', 'geoPoint': {'lat': 35.73319, 'lon': -81.3412}}, {'zip': '44118', 'city': 'South Euclid', 'state': 'Ohio', 'country': 'United States', 'facility': 'Haber Dermatology & Cosmetic Research', 'geoPoint': {'lat': 41.52311, 'lon': -81.51846}}, {'zip': '73104', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'OU Health Sciences Center-Dept. of Dermatology', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '97223', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Medical Center, PC', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '37072', 'city': 'Goodlettsville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Rivergate Dermatology', 'geoPoint': {'lat': 36.32311, 'lon': -86.71333}}, {'zip': '78759', 'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'facility': 'DermResearch, Inc.', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'zip': '77058', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Center for Clinical Studies', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Progressive Clinical Research', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '23507', 'city': 'Norfolk', 'state': 'Virginia', 'country': 'United States', 'facility': 'Virginia Clinical Research, Inc.', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}, {'zip': 'T2S 3B3', 'city': 'Calgary', 'state': 'Alberta', 'country': 'Canada', 'facility': 'The Dermatology Centre', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'zip': 'T5K 1X3', 'city': 'Edmonton', 'state': 'Alberta', 'country': 'Canada', 'facility': 'Stratica Medical', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': 'T3A2N1', 'city': 'Surrey', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Guildford Dermatology Specialists', 'geoPoint': {'lat': 49.10635, 'lon': -122.82509}}, {'zip': 'R3C 1R4', 'city': 'Winnipeg', 'state': 'Manitoba', 'country': 'Canada', 'facility': 'Dermadvance Research', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'zip': 'A1B 3E1', 'city': "St. John's", 'state': 'Newfoundland and Labrador', 'country': 'Canada', 'facility': 'Nexus Clinical Research', 'geoPoint': {'lat': 47.56494, 'lon': -52.70931}}, {'zip': 'L3P 6L2', 'city': 'Markham', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Lynderm Research, Inc.', 'geoPoint': {'lat': 43.86682, 'lon': -79.2663}}, {'zip': 'N2J 1C4', 'city': 'Waterloo', 'state': 'Ontario', 'country': 'Canada', 'facility': 'K. Papp Clinical Research, Inc.', 'geoPoint': {'lat': 43.4668, 'lon': -80.51639}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Galderma R&D', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'Marie Ciardella Clinical Trials.gov Administrator', 'oldOrganization': 'Galderma'}}}}